HIGHLIGHTS
SUMMARY
For the more severe acute distress respiratory syndrome (ARDS) patients, veno-venous extra corporeal membrane oxygenation (VV-ECMO) support is a life saving therapy. Unfortunately, because of associated conditions and ECMO-induced immune dysfunction, up to 55% of patients will subsequently develop an acquired infection during ECMO support (ECMO-AI) with implication for mortality. The authors hypothesized that MSD was associated with a reduction in the incidence of ECMO-AI among VVECMO patients. Patients were screened from each hospital from respective ECMO cohorts and all adult patients (> 18 year old) who received VV-ECMO . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.